RheumJC4 Part 2: Tapering Biologics--Why, How, and What If

Slideshow

In the second installment of a slide show based on an animated discussion by members of the rheumatology journal club (#rheumjc), partipants focus on the benefits, risks, and realities of tapering biologics in clinical practice.

Part 2 of our slide show summarizing the latest conversation of the Twitter-based rheumatology journal club #rheumjc looks into tapering of biologics for rheumatoid arthritis in actual practice.Three of the participating rheumatologists practice outside the United States, offering a noteworthy difference of perspective.The discussion in Part 1 focused on a randomized trial of biologic tapering published recently in BMJ. Here, participants focused on the clinical realities: Why to taper, whom to taper, when to start tapering, how to decide whether restarting the biologic is warranted, and what happens next.

Recent Videos
Signs and Symptoms of Connective Tissue Disease
Connective Tissue Disease Brings Dermatology & Rheumatology Together
© 2024 MJH Life Sciences

All rights reserved.